Immuron Ltd.
(NASDAQ : IMRN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 1.14%33.840.9%$1138.25m
JNJJohnson & Johnson 0.01%142.500.7%$1016.34m
BMYBristol-Myers Squibb Co. -1.17%57.431.0%$922.01m
MRKMerck & Co., Inc. 0.05%76.730.7%$787.68m
ABBVAbbVie, Inc. -1.18%96.781.9%$725.30m
LLYEli Lilly & Co. -1.84%163.391.1%$641.93m
AZNAstraZeneca Plc -0.40%53.761.2%$288.49m
RPRXRoyalty Pharma Plc -1.49%47.640.1%$203.76m
NVSNovartis AG -0.36%87.030.2%$143.34m
RGENRepligen Corp. -1.97%126.137.1%$115.34m
GSKGlaxoSmithKline Plc -1.14%39.910.2%$109.88m
NVONovo Nordisk A/S -0.26%65.440.1%$88.47m
RETAReata Pharmaceuticals, Inc. -1.10%154.403.4%$79.42m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -2.31%74.140.0%$67.56m
SNYSanofi -0.53%50.280.2%$63.74m

Company Profile

Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. It operates through the following segments: Research and Development, and HyperImmune Products.The Research and Development segment involves the R&D projects performed in Australia, Israel, and United States. The HyperImmune Products segment comprises of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.